Key Takeaways
- • At least 33 U.S. states have implemented corporate practice of medicine (CPOM) laws regulating private equity ownership in healthcare, though regulatory strength and consistency vary significantly across jurisdictions.
- • State-level regulatory frameworks focus primarily on disclosure requirements and notification mechanisms, with New York requiring healthcare organizations to notify the Department of Health about mergers, acquisitions, contracts, and partnerships involving private equity.
- • Federal oversight mechanisms including antitrust enforcement, fraud and abuse regulations, and Justice Department/FTC cross-government inquiries have been deployed to address consolidation risks and profit-generation concerns in healthcare markets under private equity ownership.
- • Existing legal and regulatory responses face structural limitations, including corporate opacity created by PE fund structures that obscure ownership chains and complicate enforcement of corporate practice restrictions.
- • Policy effectiveness remains largely unevaluated; most implemented policies lack empirical assessment of their impact on healthcare market consolidation, quality of care, or financial risk mitigation.
Summary
Private equity investment in healthcare has expanded substantially over the past two decades, prompting regulatory responses at both state and federal levels. At least 33 states currently regulate corporate practice of medicine (CPOM), establishing legal frameworks intended to restrict private equity ownership and control of healthcare delivery. However, the strength and consistency of these regulations vary considerably across jurisdictions, creating a fragmented regulatory landscape that limits systemic effectiveness.
State-level regulatory approaches emphasize disclosure and notification requirements. New York exemplifies this model by requiring healthcare organizations to notify the state Department of Health regarding mergers, acquisitions, contracts, partnerships, and other transactions that may involve private equity involvement. These disclosure mechanisms aim to create transparency and enable regulatory oversight at the point of transaction, though scholars note that most implemented policies have not undergone rigorous empirical evaluation to determine whether they achieve their stated objectives.
Federal regulatory efforts complement state initiatives through multiple enforcement channels. The Justice Department and Federal Trade Commission have launched cross-government inquiries to understand how healthcare market transactions may increase consolidation and generate profits for private equity firms. Additionally, existing federal antitrust oversight, fraud and abuse enforcement, and healthcare-specific statutes serve as tools to address risks associated with private equity acquisition patterns. Researchers studying the 2023 Merger Guidelines have examined whether federal antitrust regulations adequately address private equity investment dynamics in healthcare specifically.
A structural challenge impeding regulatory effectiveness stems from the corporate structures commonly employed by private equity funds. These entities are designed to obscure ownership chains and complicate transparency, potentially frustrating state and federal enforcement efforts. Furthermore, most capital deployed by private equity investors originates from institutional and high-wealth sources rather than the firms' own capital, creating moral hazard dynamics that encourage risk-taking without corresponding financial exposure for fund managers.
Policy development in this space remains nascent. Across seven high-income countries examined in recent research, policies addressing private equity involvement in healthcare are concentrated in disclosure and notification mechanisms, with limited evaluation of whether these tools effectively mitigate consolidation risks or protect patient interests. The challenge of crafting evidence-based policy is compounded by data limitations and difficulty isolating causal effects of private equity acquisition on healthcare market outcomes.
State-level regulatory approaches emphasize disclosure and notification requirements. New York exemplifies this model by requiring healthcare organizations to notify the state Department of Health regarding mergers, acquisitions, contracts, partnerships, and other transactions that may involve private equity involvement. These disclosure mechanisms aim to create transparency and enable regulatory oversight at the point of transaction, though scholars note that most implemented policies have not undergone rigorous empirical evaluation to determine whether they achieve their stated objectives.
Federal regulatory efforts complement state initiatives through multiple enforcement channels. The Justice Department and Federal Trade Commission have launched cross-government inquiries to understand how healthcare market transactions may increase consolidation and generate profits for private equity firms. Additionally, existing federal antitrust oversight, fraud and abuse enforcement, and healthcare-specific statutes serve as tools to address risks associated with private equity acquisition patterns. Researchers studying the 2023 Merger Guidelines have examined whether federal antitrust regulations adequately address private equity investment dynamics in healthcare specifically.
A structural challenge impeding regulatory effectiveness stems from the corporate structures commonly employed by private equity funds. These entities are designed to obscure ownership chains and complicate transparency, potentially frustrating state and federal enforcement efforts. Furthermore, most capital deployed by private equity investors originates from institutional and high-wealth sources rather than the firms' own capital, creating moral hazard dynamics that encourage risk-taking without corresponding financial exposure for fund managers.
Policy development in this space remains nascent. Across seven high-income countries examined in recent research, policies addressing private equity involvement in healthcare are concentrated in disclosure and notification mechanisms, with limited evaluation of whether these tools effectively mitigate consolidation risks or protect patient interests. The challenge of crafting evidence-based policy is compounded by data limitations and difficulty isolating causal effects of private equity acquisition on healthcare market outcomes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.